BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Denys A, Arrive L, Servois V, Dubray B, Najmark D, Sibert A, Menu Y. Hepatic tumors: detection and characterization at 1-T MR imaging enhanced with AMI-25. Radiology. 1994;193:665-669. [PMID: 7972805 DOI: 10.1148/radiology.193.3.7972805] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Alger JR, Harreld JH, Chen S, Mintorovitch J, Lu DS. Time-to-echo optimization for spin echo magnetic resonance imaging of liver metastasis using superparamagnetic iron oxide particles. J Magn Reson Imaging 2001;14:586-94. [DOI: 10.1002/jmri.1223] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
2 Chang D, Kim B, Yun Y, Hur Y, Lee Y, Choi M, Yoon J, Seong J. SUPERPARAMAGNETIC IRON OXIDE-ENHANCED MAGNETIC RESONANCE IMAGING OF THE LIVER IN BEAGLE DOGS. Veterinary Radiology & Ultrasound 2002;43:37-42. [DOI: 10.1111/j.1740-8261.2002.tb00440.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Kirchin MA, Spinazzi A. Low-Dose Gadobenate Dimeglumine-Enhanced MRI in the Detection and Characterization of Focal Liver Lesions. Academic Radiology 2002;9:S121-6. [DOI: 10.1016/s1076-6332(03)80416-6] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
4 Higashihara H, Murakami T, Kim T, Hori M, Onishi H, Nakata S, Osuga K, Tomoda K, Nakamura H. Differential diagnosis between metastatic tumors and nonsolid benign lesions of the liver using ferucarbotran-enhanced MR imaging. European Journal of Radiology 2010;73:125-30. [DOI: 10.1016/j.ejrad.2008.09.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
5 Siegelman ES, Outwater EK. Magnetic resonance imaging of focal and diffuse hepatic disease. Seminars in Ultrasound, CT and MRI 1998;19:2-34. [DOI: 10.1016/s0887-2171(98)90022-1] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
6 Low RN. Contrast agents for MR imaging of the liver. J Magn Reson Imaging 1997;7:56-67. [DOI: 10.1002/jmri.1880070109] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
7 Heiken JP. Distinguishing benign from malignant liver tumours. Cancer Imaging 2007;7 Spec No A:S1-14. [PMID: 17921080 DOI: 10.1102/1470-7330.2007.9084] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
8 Ba-Ssalamah A, Heinz-Peer G, Schima W, Schibany N, Schick S, Prokesch RW, Kaider A, Teleky B, Wrba F, Lechner G. Detection of focal hepatic lesions: comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAP. J Magn Reson Imaging 2000;11:665-72. [PMID: 10862066 DOI: 10.1002/1522-2586(200006)11:6<665::aid-jmri13>3.0.co;2-d] [Cited by in Crossref: 45] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Vogl TJ, Hammerstingl R, Schwarz W, Kümmel S, Müller PK, Balzer T, Lauten MJ, Balzer JO, Mack MG, Schimpfky C, Schrem H, Bechstein WO, Neuhaus P, Felix R. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient. Invest Radiol 1996;31:696-708. [PMID: 8915751 DOI: 10.1097/00004424-199611000-00004] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 3.0] [Reference Citation Analysis]
10 del Frate C, Bazzocchi M, Mortele KJ, Zuiani C, Londero V, Como G, Zanardi R, Ros PR. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations. Radiology. 2002;225:766-772. [PMID: 12461259 DOI: 10.1148/radiol.2253011854] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
11 Jung G, Krahe T, Kugel H, Gieseke J, Walter C, Lackner K. Detection of Focal Hepatic Lesions: Effects of Superparamagnetic Iron Oxide (AMI-25) on Magnetic Resonance Imaging of the Liver Using T2-Weighted Fast Spin-Echo Sequences and Gradient-and-Spin-Echo Sequences at 1.0 Tesla. INVESTIGATIVE RADIOLOGY 1998;33:61-7. [DOI: 10.1097/00004424-199802000-00001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
12 Hori M, Murakami T, Kim T, Iannaccone R, Abe H, Onishi H, Tomoda K, Catalano C, Passariello R, Nakamura H. Hemodynamic characterization of focal hepatic lesions: Role of ferucarbotran-enhanced dynamic MR imaging using T2-weighted multishot spin-echo echo-planar sequence. J Magn Reson Imaging 2006;23:509-19. [DOI: 10.1002/jmri.20542] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
13 Clément O, Siauve N, Lewin M, de Kerviler E, Cuénod CA, Frija G. Contrast agents in magnetic resonance imaging of the liver: present and future. Biomed Pharmacother 1998;52:51-8. [PMID: 9755795 DOI: 10.1016/S0753-3322(98)80003-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
14 Coenegrachts K, Orlent H, ter Beek L, Haspeslagh M, Bipat S, Stoker J, Rigauts H. Improved focal liver lesion detection: comparison of single-shot spin-echo echo-planar and superparamagnetic iron oxide (SPIO)-enhanced MRI. J Magn Reson Imaging. 2008;27:117-124. [PMID: 18050350 DOI: 10.1002/jmri.21247] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
15 Grazioli L, Morana G, Federle MP, Brancatelli G, Testoni M, Kirchin MA, Menni K, Olivetti L, Nicoli N, Procacci C. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology. 2001;221:731-739. [PMID: 11719669 DOI: 10.1148/radiol.2213010139] [Cited by in Crossref: 118] [Cited by in F6Publishing: 97] [Article Influence: 5.6] [Reference Citation Analysis]
16 Coenegrachts K, De Geeter F, ter Beek L, Walgraeve N, Bipat S, Stoker J, Rigauts H. Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases. Eur Radiol. 2009;19:370-379. [PMID: 18795299 DOI: 10.1007/s00330-008-1163-y] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
17 Thunus L, Lejeune R. Overview of transition metal and lanthanide complexes as diagnostic tools. Coordination Chemistry Reviews 1999;184:125-55. [DOI: 10.1016/s0010-8545(98)00206-9] [Cited by in Crossref: 107] [Article Influence: 4.7] [Reference Citation Analysis]
18 Blomley MJ, Sidhu PS, Cosgrove DO, Albrecht T, Harvey CJ, Heckemann RA, Butler-Barnes J, Eckersley RJ, Basilico R. Do different types of liver lesions differ in their uptake of the microbubble contrast agent SH U 508A in the late liver phase? Early experience. Radiology. 2001;220:661-667. [PMID: 11526264 DOI: 10.1148/radiol.2203992044] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 3.0] [Reference Citation Analysis]
19 Earls JP, Bluemke DA. NEW MR IMAGING CONTRAST AGENTS. Magnetic Resonance Imaging Clinics of North America 1999;7:255-73. [DOI: 10.1016/s1064-9689(21)00021-0] [Cited by in Crossref: 20] [Article Influence: 0.9] [Reference Citation Analysis]
20 Raynal I, Prigent P, Peyramaure S, Najid A, Rebuzzi C, Corot C. Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol 2004;39:56-63. [PMID: 14701989 DOI: 10.1097/01.rli.0000101027.57021.28] [Cited by in Crossref: 302] [Cited by in F6Publishing: 281] [Article Influence: 16.8] [Reference Citation Analysis]
21 Hirohashi S, Ueda K, Uchida H, Ono W, Takahama J, Takewa M, Kitano S, Ohishi H. Nondiffuse Fatty Change of the Liver: Discerning Pseudotumor on MR Images Enhanced with Ferumoxides—Initial Observations. Radiology 2000;217:415-20. [DOI: 10.1148/radiology.217.2.r00nv26415] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
22 Lee HJ, Lee HJ, Lee JM, Chang Y, Woo ST. Ultrasmall superparamagnetic iron oxides enhanced MR imaging in rats with experimentally induced endometriosis. Magnetic Resonance Imaging 2012;30:860-8. [DOI: 10.1016/j.mri.2012.02.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
23 Grazioli L, Morana G, Kirchin MA, Caccia P, Romanini L, Bondioni MP, Procacci C, Chiesa A. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): An intra-individual comparison. J Magn Reson Imaging 2003;17:593-602. [DOI: 10.1002/jmri.10289] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
24 Oswald P, Clement O, Chambon C, Schouman-claeys E, Frija G. Liver positive enhancement after injection of superparamagnetic nanoparticles: Respective role of circulating and uptaken particles. Magnetic Resonance Imaging 1997;15:1025-31. [DOI: 10.1016/s0730-725x(97)00004-0] [Cited by in Crossref: 75] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
25 Martí-bonmatí L, Casillas C, Dosdá R. Enhancement characteristics of hepatic focal nodular hyperplasia and its scar by dynamic magnetic resonance imaging. MAGMA 2000;10:200-4. [DOI: 10.1007/bf02590646] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
26 Högström B. Efficacy assessment of imaging technologies and contrast media. Academic Radiology 1996;3:859-64. [DOI: 10.1016/s1076-6332(96)80278-9] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
27 Takeshita K, Nagashima I, Frui S, Takada K, Yamauchi T, Harasawa A, Oba H, Kohtake H, Tanaka H, Suzuki S. Effect of Superparamagnetic Iron Oxide-Enhanced MRI of the Liver With Hepatocellular Carcinoma and Hyperplastic Nodule: . Journal of Computer Assisted Tomography 2002;26:451-5. [DOI: 10.1097/00004728-200205000-00024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
28 Mahfouz A, Hamm B. CONTRAST AGENTS. Magnetic Resonance Imaging Clinics of North America 1997;5:223-40. [DOI: 10.1016/s1064-9689(21)00194-x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
29 Cho ES, Yu JS, Ahn JH, Park MS, Kim JH, Chung JJ, Kim KW. Ferucarbotran-enhanced T2-weighted magnetic resonance imaging: differentiation of hepatic cavernous hemangiomas from malignant solid lesions. Abdom Imaging 2009;34:494-501. [PMID: 18546032 DOI: 10.1007/s00261-008-9430-6] [Reference Citation Analysis]
30 Li K, Chan F. Advances in imaging techniques for the diagnosis of focal hepatic lesions. Journal of Gastroenterology and Hepatology 2009;14:S22-7. [DOI: 10.1046/j.1440-1746.1999.01872.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Raman SS, Lu DS, Chen SC, Sayre J, Eilber F, Economou J. Hepatic MR imaging using ferumoxides: prospective evaluation with surgical and intraoperative sonographic confirmation in 25 cases. AJR Am J Roentgenol 2001;177:807-12. [PMID: 11566677 DOI: 10.2214/ajr.177.4.1770807] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
32 Ji H, Ros PR. Magnetic resonance imaging. Liver-specific contrast agents. Clin Liver Dis 2002;6:73-90. [PMID: 11933597 DOI: 10.1016/s1089-3261(03)00067-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
33 Ward J, Chen F, Guthrie JA, Wilson D, Lodge JP, Wyatt JI, Robinson PJ. Hepatic lesion detection after superparamagnetic iron oxide enhancement: comparison of five T2-weighted sequences at 1.0 T by using alternative-free response receiver operating characteristic analysis. Radiology. 2000;214:159-166. [PMID: 10644117 DOI: 10.1148/radiology.214.1.r00ja21159] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 2.6] [Reference Citation Analysis]
34 Kumano S, Murakami T, Kim T, Hori M, Okada A, Sugiura T, Noguchi Y, Kawata S, Tomoda K, Nakamura H. Using superparamagnetic iron oxide-enhanced MRI to differentiate metastatic hepatic tumors and nonsolid benign lesions. AJR Am J Roentgenol 2003;181:1335-9. [PMID: 14573430 DOI: 10.2214/ajr.181.5.1811335] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
35 Bartolozzi C, Donati F, Cioni D, Procacci C, Morana G, Chiesa A, Grazioli L, Cittadini G, Cittadini G, Giovagnoni A. Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT. Eur Radiol. 2004;14:14-20. [PMID: 14730384 DOI: 10.1007/s00330-003-1966-9] [Cited by in Crossref: 95] [Cited by in F6Publishing: 77] [Article Influence: 5.0] [Reference Citation Analysis]
36 Paley MR, Mergo PJ, Torres GM, Ros PR. Characterization of focal hepatic lesions with ferumoxides-enhanced T2-weighted MR imaging. AJR Am J Roentgenol. 2000;175:159-163. [PMID: 10882267 DOI: 10.2214/ajr.175.1.1750159] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 2.9] [Reference Citation Analysis]
37 Frate CD, Zuiani C, Londero V, Como G, Bazzocchi M, Mortele K, Ros PR. Comparing Levovist-Enhanced Pulse Inversion Harmonic Imaging and Ferumoxides-Enhanced MR Imaging of Hepatic Metastases. American Journal of Roentgenology 2003;180:1339-46. [DOI: 10.2214/ajr.180.5.1801339] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
38 Coenegrachts K. Magnetic resonance imaging of the liver: New imaging strategies for evaluating focal liver lesions. World J Radiol 2009; 1(1): 72-85 [PMID: 21160723 DOI: 10.4329/wjr.v1.i1.72] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
39 Cheng WZ, Zeng MS, Yan FH, Rao SX, Shen JZ, Chen CZ, Zhang SJ, Shi WB. Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions. World J Gastroenterol 2007; 13(36): 4891-4896 [PMID: 17828821 DOI: 10.3748/wjg.v13.i36.4891] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
40 Knollmann FD, Böck JC, Teltenkötter S, Wlodarczyk W, Mühler A, Vogl TJ, Felix R. Evaluation of portal MR angiography using superparamagnetic iron oxide. J Magn Reson Imaging 1997;7:191-6. [DOI: 10.1002/jmri.1880070129] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
41 Coenegrachts K, Matos C, ter Beek L, Metens T, Haspeslagh M, Bipat S, Stoker J, Rigauts H. Focal liver lesion detection and characterization: comparison of non-contrast enhanced and SPIO-enhanced diffusion-weighted single-shot spin echo echo planar and turbo spin echo T2-weighted imaging. Eur J Radiol 2009;72:432-9. [PMID: 18849130 DOI: 10.1016/j.ejrad.2008.09.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
42 Zhang F, Huang X, Qian C, Zhu L, Hida N, Niu G, Chen X. Synergistic enhancement of iron oxide nanoparticle and gadolinium for dual-contrast MRI. Biochem Biophys Res Commun 2012;425:886-91. [PMID: 22898051 DOI: 10.1016/j.bbrc.2012.07.168] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
43 Kim JH, Kim MJ, Suh SH, Chung JJ, Yoo HS, Lee JT. Characterization of focal hepatic lesions with ferumoxides-enhanced MR imaging: utility of T1-weighted spoiled gradient recalled echo images using different echo times. J Magn Reson Imaging 2002;15:573-83. [PMID: 11997899 DOI: 10.1002/jmri.10102] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
44 Tanimoto A, Satoh Y, Yuasa Y, Jinzaki M, Hiramatsu K. Performance of Gd-EOB-DTPA and superparamagnetic iron oxide particles in the detection of primary liver cancer: A comparative study by alternative free-response receiver operating characteristic analysis. J Magn Reson Imaging 1997;7:120-4. [DOI: 10.1002/jmri.1880070116] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 0.9] [Reference Citation Analysis]
45 Kim YK, Lee JM, Kim CS. Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 2004;14:5-13. [PMID: 14600778 DOI: 10.1007/s00330-003-2115-1] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 3.7] [Reference Citation Analysis]
46 Petersein J, Saini S, Weissleder R. LIVER II: IRON OXIDE-BASED RETICULOENDOTHELIAL CONTRAST AGENTS FOR MR IMAGING. Magnetic Resonance Imaging Clinics of North America 1996;4:53-60. [DOI: 10.1016/s1064-9689(21)00553-5] [Cited by in Crossref: 18] [Article Influence: 0.7] [Reference Citation Analysis]
47 Limanond P, Raman SS, Sayre J, Lu DS. Comparison of dynamic gadolinium-enhanced and ferumoxides-enhanced MRI of the liver on high- and low-field scanners. J Magn Reson Imaging 2004;20:640-7. [DOI: 10.1002/jmri.20165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
48 Namkung S, Zech CJ, Helmberger T, Reiser MF, Schoenberg SO. Superparamagnetic iron oxide (SPIO)-enhanced liver MRI with ferucarbotran: efficacy for characterization of focal liver lesions. J Magn Reson Imaging 2007;25:755-65. [PMID: 17335040 DOI: 10.1002/jmri.20873] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
49 Chou CT, Chen RC, Chen WT, Lii JM. Percentage of signal intensity loss for characterisation of focal liver lesions in patients with chronic liver disease using ferucarbotran-enhanced MRI. Br J Radiol 2010;83:1023-8. [PMID: 20413445 DOI: 10.1259/bjr/21476692] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
50 Li KC, Chan F. New approaches to the investigation of focal hepatic lesions. Best Practice & Research Clinical Gastroenterology 1999;13:529-43. [DOI: 10.1053/bega.1999.0046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
51 Lutz AM, Willmann JK, Goepfert K, Marincek B, Weishaupt D. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging. Radiology. 2005;237:520-528. [PMID: 16192317 DOI: 10.1148/radiol.2372041183] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
52 van Aalten SM, Witjes CD, de Man RA, Ijzermans JN, Terkivatan T. Can a decision-making model be justified in the management of hepatocellular adenoma? Liver Int. 2012;32:28-37. [PMID: 22098685 DOI: 10.1111/j.1478-3231.2011.02667.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
53 Lencioni R, Donati F, Cioni D, Paolicchi A, Cicorelli A, Bartolozzi C. Detection of colorectal liver metastases: prospective comparison of unenhanced and ferumoxides-enhanced magnetic resonance imaging at 1.5 T, dual-phase spiral CT, and spiral CT during arterial portography. MAGMA 1998;7:76-87. [DOI: 10.1007/bf02592232] [Cited by in Crossref: 33] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
54 Savranoglu P, Obuz F, Karasu S, Coker A, Secil M, Sagol O, Igci E, Dicle O, Astarcioglu I. The role of SPIO-enhanced MRI in the detection of malignant liver lesions. Clin Imaging 2006;30:377-81. [PMID: 17101405 DOI: 10.1016/j.clinimag.2006.06.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
55 Helmberger T, Semelka RC. NEW CONTRAST AGENTS FOR IMAGING THE LIVER. Magnetic Resonance Imaging Clinics of North America 2001;9:745-66. [DOI: 10.1016/s1064-9689(21)00272-5] [Cited by in Crossref: 17] [Article Influence: 0.8] [Reference Citation Analysis]
56 Kim YK, Lee JM, Kim CS, Chung GH, Kim CY, Kim IH. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 2005;15:220-8. [DOI: 10.1007/s00330-004-2570-3] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 3.8] [Reference Citation Analysis]
57 Saini S, Edelman RR, Li W, Petersein J, Hahn PF. Clinical evaluation of ultrasmall superparamagnetic iron oxide particles for liver imaging. Academic Radiology 1996;3:S409-12. [DOI: 10.1016/s1076-6332(96)80600-3] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
58 Park SM, Aalipour A, Vermesh O, Yu JH, Gambhir SS. Towards clinically translatable in vivo nanodiagnostics. Nat Rev Mater 2017;2:17014. [PMID: 29876137 DOI: 10.1038/natrevmats.2017.14] [Cited by in Crossref: 142] [Cited by in F6Publishing: 132] [Article Influence: 28.4] [Reference Citation Analysis]
59 Poeckler–schoeniger C, Koepke J, Gueckel F, Sturm J, Georgi M. MRI with superparamagnetic iron oxide: efficacy in the detection and characterization of focal hepatic lesions. Magnetic Resonance Imaging 1999;17:383-92. [DOI: 10.1016/s0730-725x(98)00180-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 7] [Article Influence: 2.1] [Reference Citation Analysis]
60 Kwak HS, Lee JM, Kim YK, Lee YH, Kim CS. Detection of hepatocellular carcinoma: comparison of ferumoxides-enhanced and gadolinium-enhanced dynamic three-dimensional volume interpolated breath-hold MR imaging. Eur Radiol 2005;15:140-7. [PMID: 15449000 DOI: 10.1007/s00330-004-2508-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
61 Morana G, Grazioli L, Testoni M, Caccia P, Procacci C. Contrast Agents for Hepatic Magnetic Resonance Imaging: . Topics in Magnetic Resonance Imaging 2002;13:117-50. [DOI: 10.1097/00002142-200206000-00002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
62 Kang BK, Lim JH, Kim SH, Choi D, Lim HK, Lee WJ, Lee SJ. Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT. Radiology. 2003;226:79-85. [PMID: 12511672 DOI: 10.1148/radiol.2261011827] [Cited by in Crossref: 73] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
63 Pirovano G, Vanzulli A, Marti-Bonmati L, Grazioli L, Manfredi R, Greco A, Holzknecht N, Daldrup-Link HE, Rummeny E, Hamm B. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. AJR Am J Roentgenol. 2000;175:1111-1120. [PMID: 11000175 DOI: 10.2214/ajr.175.4.1751111] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 3.4] [Reference Citation Analysis]
64 Ishida T, Murakami T, Kato N, Takahashi M, Miyazawa T, Tsuda K, Tomoda K, Narumi Y, Nakamura H. Superparamagnetic Iron Oxide Enhanced Magnetic Resonance Imaging of Rat Liver with Hepatocellular Carcinoma and Benign Hyperplastic Nodule: . INVESTIGATIVE RADIOLOGY 1997;32:282-7. [DOI: 10.1097/00004424-199705000-00005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]